BiovelocITA
BiovelocITA is Italy's first biotech accelerator, founded in 2015, that invests capital and provides strategic management to transform early-stage Italian life sciences research into operational biotech companies across oncology, gene editing, diabetes, and rare diseases.
- Company typePrivate
- Founded2015
- HeadquartersMilano, Italy
- Headcount1–10
- GTM typeB2B
- OfferingServices
What BiovelocITA does
BiovelocITA S.r.l. is Italy's first biotech accelerator, founded in 2015 in Milan by serial biotech entrepreneurs Silvano Spinelli (Chairman) and Gabriella Camboni (CEO), alongside Sofinnova Partners as a founding partner. The company identifies promising early-stage Italian scientific research projects and provides capital plus strategic and management expertise to transform them into operational biotech companies, with a focus on red biotech therapeutic areas including oncology, rare genetic diseases, diabetes, infectious diseases, and amyloidosis. Its portfolio includes three operating companies (Enthera Pharmaceuticals in diabetes/gastroenterology, Alia Therapeutics in CRISPR/Cas9 gene editing, and Amypopharma in nanoparticle-based amyloidosis therapy) plus additional research projects in collaboration with leading Italian institutions such as IFOM, Ospedale San Raffaele, Istituto Superiore di Sanità, CIBIO at the Università di Trento, Università Milano-Bicocca, and Università Magna Graecia di Catanzaro.
The company's business model is equity investment rather than fee-for-service: BiovelocITA deploys capital into selected startups and research projects in exchange for equity stakes, with returns generated through portfolio company exits via M&A or public offerings. The company has raised over 14 million euros across two capital increases (7 million euros in 2016 and 7.245 million euros in 2017) from founders, Atlante Seed (Intesa Sanpaolo group), and private investors coordinated by BANOR SIM and Banca Profilo. Go-to-market relies on proactive scouting of university research, exclusive partnerships with Italian research institutions, and the founders' proven track record of building and exiting biotech companies (EOS sold to Clovis Oncology for 470 million dollars in 2013, Novuspharma IPO in 2000). Distribution operates through a direct investment model, with TTFactor providing structured technology transfer pathways to commercial licensing.
Notable portfolio achievements include Enthera's 28 million euro Series A round in 2019 to advance type 1 diabetes and inflammatory bowel disease therapies, Alia Therapeutics' position as Italy's first company active in treating genetic diseases with genome editing, and Amypopharma's two granted patents in nanoparticle amyloidosis therapy. The company maintains a lean team of 1-10 employees and concentrates exclusively on the Italian market, leveraging Sofinnova's international VC network and the founders' relationships with international pharma acquirers to support portfolio exits.
BiovelocITA firmographics
Firmographics- Name
- BiovelocITA
- Legal name
- BiovelocITA S.r.l.
- Website
- http://www.biovelocita.com/
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BiovelocITA is Italy's first biotech accelerator, founded in 2015, that invests capital and provides strategic management to transform early-stage Italian life sciences research into operational biotech companies across oncology, gene editing, diabetes, and rare diseases.
- Ownership category
- akta.pro rank
BiovelocITA industry classification
Industry- Product category
- Biotech Accelerator and Investment Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Portfolio Management and Investment Advice (523940)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Investment Advice (6282)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI), Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN), Health & Medical Research Grantmaking Foundations (BPAGAKAL)
Keywords
Where BiovelocITA is headquartered
LocationHeadquarters
- HQ city
- Milano
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
BiovelocITA business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Equity Investment Returns: BiovelocITA invests capital in biotech startups in exchange for equity stakes. Returns are generated through portfolio company exits via M&A or public offerings. The company was founded by serial biotech entrepreneurs (Spinelli and Camboni) who previously sold EOS to Clovis Oncology for $470 million and built Novuspharma through to acquisition.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
BiovelocITA product offering
Product offeringCore offering
BiovelocITA is Italy's first biotech accelerator that identifies, funds, and supports the development of promising life sciences research projects into operational biotech companies. It provides seed capital, strategic management expertise, and operational guidance to bridge Italian academic research from laboratory discovery through proof-of-concept and into clinical development, taking equity stakes in portfolio companies spanning gene editing, diabetes therapy, amyloidosis treatment, oncology, and infectious disease vaccines.
Product overview
BiovelocITA is the first Italian biotech accelerator that identifies, funds, and supports the development of promising life sciences research projects into successful biotech companies. Rather than offering a single product or platform, BiovelocITA operates a portfolio of startup companies and research projects across multiple therapeutic areas including oncology, diabetes, infectious diseases, amyloidosis, and gene editing. The accelerator provides capital and strategic-management expertise to transform laboratory discoveries into operational industrial ventures, with notable portfolio companies including Enthera Pharmaceuticals (diabetes therapy), Alia Therapeutics (CRISPR gene editing), and Amypopharma (amyloidosis treatment), alongside collaborative research projects with institutions such as Istituto Superiore di Sanità, Università Magna Graecia, and IFOM.
Differentiator
Problem solved
Functional benefit
Products and services
- Biotech Acceleration Program End-to-end accelerator service for Italian biotech research projects, providing seed capital, strategic management, operational support, and proof-of-concept development through to clinical phases. Intended for Italian academic spin-offs and biotech startups developing red biotech therapeutics.
- Enthera Pharmaceuticals (Portfolio Company) Portfolio company founded in collaboration with Ospedale San Raffaele focused on developing therapies for type 1 diabetes and inflammatory bowel diseases. Enthera raised €28 million in Series A funding.
- Alia Therapeutics (Portfolio Company) Italy's first company dedicated to treating genetic diseases using CRISPR/Cas9 gene editing technologies, developing evoCas9 precision molecular scissors for therapeutic applications. Spin-off of CIBIO at the University of Trento.
- Amypopharma (Portfolio Company) Spin-off of Università Milano-Bicocca developing nanoparticles for amyloidosis therapy, focusing on protein fibril accumulation diseases including Alzheimer's. Based on research by Professor Massimo Masserini and Dr. Francesca Re with 60+ publications and two granted patents.
Quantifiable outcome
- EOS (previous company by founders) was acquired by Clovis Oncology in November 2013 for $470 million
- +2 more outcomes
Companies that use BiovelocITA
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
BiovelocITA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
BiovelocITA partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core research partner, research partner, spin-off partner and core partner.
- Istituto Superiore di Sanità (ISS)core research partnerItaly's leading public health research institute. BiovelocITA collaborates with Dr. Maurizio Federico's team to develop innovative therapeutic vaccine platform against cancer and chronic infectious diseases using extracellular vesicle technology.
- Università Magna Graecia di Catanzaroresearch partnerBiovelocITA supports Professor Pierfrancesco Tassone's project developing targeted antibody therapy against CD43 protein for treatment of childhood and adult leukemia.
- Università Milano Bicoccaspin-off partnerBiovelocITA holds a stake in Amypopharma, a spin-off developing nanoparticles for amyloidosis therapy based on research by Professor Massimo Masserini and Dr. Francesca Re with 60+ publications and two granted patents.
- CIBIO (Università di Trento)core research partnerDipartimento di Biologia Cellulare, Computazionale e Integrata. Home to Anna Cereseto's laboratory that developed evoCas9 precision gene editing technology. CIBIO spin-off Alia Therapeutics is BiovelocITA's portfolio company.
- TTFactor (IFOM/IEO Technology Transfer)core partnerTechnology transfer company founded by IFOM and IEO that negotiates licensing agreements for commercial rights. At project conclusion, exclusive commercial licenses will be conferred to IFOM/BiovelocITA co-participated spin-offs.
- IFOM (Istituto FIRC di Oncologia Molecolare)core research partnerInternational excellence in molecular oncology research. BiovelocITA collaborates with IFOM's Dr. Fabrizio d'Adda di Fagagna on DNA damage signaling and repair mechanisms for novel cancer therapeutics, with potential applications in aging-related diseases.
- Ospedale San Raffaelecore research partnerLeading Milan research hospital. BiovelocITA co-founded Enthera with Professor Paolo Fiorina to develop therapies targeting IGFBP3 hormone role in diabetic enteropathy and diabetes complications.
Scale indicators3 records
Recent moves8 records
Expansion highlights5 records
BiovelocITA competitors and assessment
Company assessmentBroad incumbents
- Sofinnova Partners: Leading European life-sciences VC (€1.3B+ AUM) that is also BiovelocITA's founding partner. Overlaps directly as a biotech investor in European therapeutic assets, but operates at far greater scale and geographic breadth.
- Forbion: Pan-European biotech investor with funds backing early-to-growth therapeutic platforms; competes with BiovelocITA for European academic spin-out deals and Series A follow-on participation.
- Pontifax Venture Capital: Israel-based biotech VC investing in therapeutic companies from early to clinical stage; overlaps in modality and stage of investment but operates outside Italy.
- TVM Capital Life Science: European healthcare/life-sciences investor providing early-to-growth equity to biotech companies — comparable in stage and therapeutic focus but with significantly larger AUM.
Direct peers
- BioGeneration Ventures: Dutch biotech seed/early-stage VC that builds companies from academic science in similar therapeutic areas (oncology, rare disease) — a directly comparable European academic-translation platform.
- Atlas Venture: US-/UK-based biotech-focused VC that forms, finances, and builds companies from academic science across modalities (gene editing, cell therapy, RNA) — a closely comparable accelerator-style model.
- Medicxi: European life-sciences VC focused on early-stage asset-centric investing from academic origins — directly analogous model of translating European academic discoveries into biotech companies.
- BioMedPartners: Swiss biotech VC financing early-stage therapeutic companies emerging from European academic research — a directly comparable European academic-translation platform.
Regional players
- Italian Angels for Growth: Italian business angel network that co-invests in Italian early-stage ventures including biotech — competes for and co-invests in the same Italian academic spin-off deal flow.
Others
- Intesa Sanpaolo (via Indaco SGR / Atlante Seed): Italian banking group whose venture arm (Atlante Seed, managed by Indaco SGR) is a BiovelocITA investor — relevant ecosystem participant providing capital but also a potential allocator of competing accelerator/incubator vehicles.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
BiovelocITA social profiles
Digital presenceBiovelocITA financial estimates
Financial estimateRevenue estimate
Valuation estimate
BiovelocITA leadership team
Management profileNumber of profiles
Profiles5 records
BiovelocITA subsidiaries and ownership
Company hierarchySubsidiaries3 records
BiovelocITA funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BiovelocITA M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BiovelocITA
What does BiovelocITA do?
BiovelocITA is Italy's first biotech accelerator that identifies, funds, and supports the development of promising life sciences research projects into operational biotech companies. It provides seed capital, strategic management expertise, and operational guidance to bridge Italian academic research from laboratory discovery through proof-of-concept and into clinical development, taking equity stakes in portfolio companies spanning gene editing, diabetes therapy, amyloidosis treatment, oncology, and infectious disease vaccines.
Is BiovelocITA a public or private company?
BiovelocITA is a private company. It is classified as venture growth investor backed and is currently operating.
When was BiovelocITA founded?
BiovelocITA was founded in 2015. It employs 1 to 10 people.
Where is BiovelocITA based?
BiovelocITA is headquartered in Milano, Italy, in the Europe region.
How does BiovelocITA make money?
One revenue line is on record: equity Investment Returns.
Who are BiovelocITA's main competitors?
Broad incumbents on record are Sofinnova Partners, Forbion, Pontifax Venture Capital and TVM Capital Life Science. Direct peers are BioGeneration Ventures, Atlas Venture, Medicxi and BioMedPartners. Italian Angels for Growth is listed as a regional player. Intesa Sanpaolo (via Indaco SGR / Atlante Seed) is listed as an others.
Does BiovelocITA have an API?
No public API is recorded for BiovelocITA.
What industry is BiovelocITA in?
BiovelocITA's product category is Biotech Accelerator and Investment Services. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 8731.